OXACILLIN SODIUM - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for oxacillin sodium and what is the scope of patent protection?
Oxacillin sodium
is the generic ingredient in four branded drugs marketed by Glaxosmithkline, Ani Pharms, Apothecon, Teva, Baxter Hlthcare, Elkins Sinn, Eugia Pharma Speclts, Fresenius Kabi Usa, Hospira, Istituto Bio Ita Spa, Onesource Specialty, Piramal Critical, Sagent Pharms, Sandoz, Watson Labs Inc, and Wockhardt Bio Ag, and is included in thirty-one NDAs. Additional information is available in the individual branded drug profile pages.There are thirty-two drug master file entries for oxacillin sodium. Six suppliers are listed for this compound.
Summary for OXACILLIN SODIUM
| US Patents: | 0 |
| Tradenames: | 4 |
| Applicants: | 16 |
| NDAs: | 31 |
| Drug Master File Entries: | 32 |
| Finished Product Suppliers / Packagers: | 6 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 2 |
| Patent Applications: | 28 |
| What excipients (inactive ingredients) are in OXACILLIN SODIUM? | OXACILLIN SODIUM excipients list |
| DailyMed Link: | OXACILLIN SODIUM at DailyMed |
Recent Clinical Trials for OXACILLIN SODIUM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Haining Health-Coming Biotech Co., Ltd. | Phase 2 |
| Alphacait, LLC | Phase 2 |
| Fundação de Amparo à Pesquisa do Estado de São Paulo | Phase 4 |
Pharmacology for OXACILLIN SODIUM
| Drug Class | Penicillin-class Antibacterial |
Medical Subject Heading (MeSH) Categories for OXACILLIN SODIUM
Anatomical Therapeutic Chemical (ATC) Classes for OXACILLIN SODIUM
US Patents and Regulatory Information for OXACILLIN SODIUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Istituto Bio Ita Spa | OXACILLIN SODIUM | oxacillin sodium | INJECTABLE;INJECTION | 062798-003 | Dec 11, 1995 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Watson Labs Inc | OXACILLIN SODIUM | oxacillin sodium | INJECTABLE;INJECTION | 062856-002 | Oct 26, 1988 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva | OXACILLIN SODIUM | oxacillin sodium | FOR SOLUTION;ORAL | 062252-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch